TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. KalVista Pharmaceuticals, Inc. is placed twelfth on our list.

TheFly reported on January 29 that TD Cowen analyst Stacy Ku raised its price target on KALV to $35 from $30 and maintained a Buy rating. The adjustment followed an update to the firm’s financial model ahead of KALV’s upcoming fourth-quarter results.

Additionally, earlier on January 9, H.C. Wainwright analyst Andrew Fein also raised the price target on KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) to $37 from $27 and maintained a Buy rating. The firm said its confidence is supported by the company’s reported fiscal 2025 EKTERLY revenue, which reinforces the view that an oral treatment is likely to become the preferred on-demand therapy for hereditary angioedema.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is a clinical-stage biopharmaceutical company developing small-molecule protease inhibitors to treat rare and serious diseases, including hereditary angioedema and diabetic macular edema. The company focuses on oral and targeted therapies designed to improve patient outcomes and quality of life.

While we acknowledge the potential of KALV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.